Moderna, Inc. announced positive interim Phase I clinical data of mRNA-1273, its vaccine candidate against SARS-CoV-2, led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Immunogenicity data are currently available for the 25 µg and 100 µg dose level after two doses (day 43) and at the 250 µg level after one dose (day 29). Dose dependent increases in immunogenicity were seen across the three dose levels, and between prime...